Palisade Bio, University of California Team Up For Target Identification, Discovery, Development

Palisade Bio Inc PALI has entered into an exclusive license with the Regents of the University of California, expanding its technology for detecting enzymatic protease activity in human clinical samples.
Under the terms of this agreement, the Company receives a worldwide exclusive license to patent rights covering certain engineered substrates and their use in measuring degradative enzymes for disease conditions.
Price Action: PALI shares are up 3.28% at $3.78 during the market session on the last check Tuesday.